HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Suzhou Dongshan Precision Manufacturing (A/H Listing) - The Turning Point Has Occurred

Pre-IPO Ingenic Semiconductor (PHIP Updates) - Some Points Worth the Attention

Ingenic Semiconductor (300223 CH | 3223 HK): Dual Primary Listing (A+H) Initiation

Pre-IPO HLA Group (A/H Listing) - The Outlook Is Not Optimistic

Pre-IPO Zhejiang Shimai Pharmaceutical - It Might Never Be Possible to Make Money

Pre-IPO WinHealth International Holding- A BD-Driven Model May Not Guarantee Sustainable High Growth

Equity Capital Markets

Zenshine Pharmaceuticals (Nanjing) Group / Equity Capital Markets

Zenshine Pharmaceuticals (Nanjing) Group (ZPN HK)

<ul>
<li>The future competitive landscape of the influenza drug market is deteriorating, and Zenshine is facing significant competitive pressure. Despite the cooperation with<a href="https://www.smartkarma.com/entities/hubei-jumpcan-pharmaceut-a" target="_blank" data-smartkarma-citation="entities:9182:1" rel="noopener"> Jumpcan Pharmaceut</a>ical, the commercialization outlook is highly uncertain.</li>
<li>Zenshine's financial situation is highly dependent on the sales performance of sebaloxavir marboxil. If commercialization fails, it will pose a direct threat to the Company's survival.</li>
<li>This is vastly different from the valuation of other biotech with validated products on the market. So, we think valuation of Zenshine would be lower than the industry average P/S.</li>
</ul>


The future competitive landscape of the influenza drug market is deteriorating, and Zenshine is facing significant competitive pressure. Despite the cooperation with Jumpcan Pharmaceutical, the commercialization outlook is highly uncertain.
Zenshine's financial situation is highly dependent on the sales performance of sebaloxavir marboxil. If commercialization fails, it will pose a direct threat to the Company's survival.
This is vastly different from the valuation of other biotech with validated products on the market. So, we think valuation of Zenshine would be lower than the industry average P/S.


Pre-IPO Zenshine Pharmaceuticals (Nanjing) Group - The Core Product Faces Significant Challenges